Akebia Therapeutics soars with Vafseo's success and rising Auryxia sales in 2025
Akebia Therapeutics reported strong financial growth in 2025, driven by the commercial success of Vafseo and rising Auryxia sales. The company's total revenue climbed to $236.2 million, up from $160.2 million the previous year. Key milestones included expanded access to Vafseo and improved patient adherence to the treatment.
Vafseo's performance stood out in 2025, with net product revenue reaching $45.8 million for the year and $6.2 million in the fourth quarter. However, Q4 revenue was impacted by a $4.8 million inventory reduction at US Renal Care. Patient adherence improved significantly, with first refill rates hitting approximately 91% among observed dosing patients by the end of the year.
The drug's market reach expanded, with 290,000 dialysis patients gaining access through protocol adoption by major organisations. Earlier clinical trials, such as PRO2TECT and INNO2VATE, had already shown Vafseo's comparable effectiveness to Darbepoetin, along with a better safety profile for treating renal anemia. Newer data further supported its benefits, revealing a 7.7% lower annual hospitalization rate and around 15% lower Medicare costs for Vafseo-treated patients.
Auryxia also contributed to the company's growth, with net revenue rising to $181.5 million in 2025, up from $152.2 million in 2024. Fourth-quarter sales reached $48.1 million, compared to $44.4 million in the same period the previous year. Despite this success, Akebia expects increased generic competition for Auryxia in 2026, which could reduce its revenue.
Beyond its commercial products, the company advanced its pipeline. Targeted trials for praliciguat, AKB-097, and AKB-9090 progressed, with clear milestones outlined for the coming year.
Akebia Therapeutics closed 2025 with total revenues of $236.2 million, marking a substantial increase from the prior year. The growth was largely fueled by Vafseo's U.S. launch and stronger Auryxia sales. Looking ahead, the company anticipates challenges from generic competition while continuing to develop its pipeline of new treatments.
